Search academic texts

Information × Registration Number 0226U001720, (0123U101245) , R & D reports Title Study of the effect of anticoagulants on the processes of metastasis and the effectiveness of antitumor therapy (experimental research) popup.stage_title Дослідження впливу комбінацій антикоагулянтів прямої (Сулодексід, Беміпарин натрію) та непрямої дії (Неодикумарин) з платиновмісним протипухлинним препаратом (Цисплатин) на метастатичну активність епідермоїдної карциноми легенів Льюїс та систему коагуліційного гемостазу Head Karatsuba Tetiana A., Кандидат біологічних наук Registration Date 30-01-2026 Organization Institute of Pharmacology and Toxicology of the National Academy of Medical Sciences of Ukraine popup.description1 To investigate in an experiment the effect of anticoagulants of direct and indirect action on the processes of metastasis under the conditions of the use of antitumor agents. popup.description2 Sulodexide (2.0 mg/kg) under these experimental conditions inhibited formation of metastases in the lungs by 63.79 % and volume of metastases by 96.91 %. When using sulodexide with cisplatin, the inhibition of formation of metastases in the lungs was 97.42 %, the volume of metastases decreased by 100.0 %. Inhibition of the growth of the primary tumor by volume was 41.01 %; the average life expectancy increased significantly (32.94 %). Enoxaparin (10.0 mg/kg) under these experimental conditions inhibited formation of metastases in the lungs by 60.88 %, and metastases volume by 96.88 %. The enoxaparin introduction with cisplatin inhibited metastases formation in lungs by 84.16 %, metastases volume decreased by 97.75 %. Inhibition of primary tumor by volume by 30.19 %; average life expectancy increased significantly (36.12 %). Comparative analysis of obtained data revealed a significant decrease in the metastatic activity of Lewis lung carcinoma (LLC) under conditions of use of direct-acting anticoagulants sulodexide and enoxaparin with cisplatin, than using cisplatin as monotherapy. Acenocoumarol (1.0 mg/kg) under these experimental conditions inhibited formation of metastases in the lungs by 63.6 %, and metastases volume by 97.9 %. When using acenocoumarol with cisplatin, the lung metastasis inhibition was 81.9 %, metastases volume decreased by 100.0 %. Inhibition of primary tumor growth by volume was 40.7 %; average life expectancy increased significantly (34.4 %). Changes in relative width of platelet distribution by volume were found, which are associated with progression of LLC metastasis. This indicator increased by (15.21–41.65) % and can be a predictor of metastasis. In presence of LLC, content of megakaryocytes in bone marrow of experimental mice decreases by (23.9–28.3) % to animals without tumors. The administration of sulodexide, enoxaparin and acenocoumarol causes an increase in content of megakaryocytes compared to animals with LLC without treatment. Product Description popup.authors Tetiana A. Bukhtiarova Oleksii M. Puskov Maksym A. Munko Serhii V. Maksiuta Denys O. Cherviovskyi popup.nrat_date 2026-01-30 Close